Neurodegeneration in diabetic retina and its potential drug targets

Current Neuropharmacology

Volumn 12, Issue 4, 2014, Pages 380-386

  Ola, Mohammad Shamsul ^a   Alhomida, Abdullah S ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Metabolites; Neurodegeneration; Neurons; Neurotrophic factor; Retina

Indexed keywords

GLUTAMIC ACID; HOMOCYSTEINE; KYNURENIC ACID; NEUROTROPHIN; VITAMIN;

APOPTOSIS; ARTICLE; DIABETIC RETINOPATHY; HUMAN; HYPERGLYCEMIA; LIPID PEROXIDATION ASSAY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT;

EID: 84911493946     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X12666140619205024     Document Type: Article

References (92)

1. Jackson, G. R., Barber, A. J. Visual dysfunction associated with diabetic retinopathy. Curr. Diab. Rep., 2010, 10, 380-4. http://dx. doi. org/10. 1007/s 11892-010-0132-4.
2. Bearse, M. A. Jr., Han, Y., Schneck, M. E., Adams, A. J. Retinal function in normal and diabetic eyes mapped with the slow flash multifocal electroretinogram. Invest. Ophthalmol. Vis. Sci., 2004, 45, 296-304. http://dx. doi. org/10. 1167/iovs. 03-0424.
3. Fletcher, E. L., Phipps, J. A., Ward, M. M., Puthussery, T., Wilkinson-Berka, J. L. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr. Pharm. Des. 2007, 13, 2699-712. http://dx. doi. org/10. 2174/138161207781662920.
4. Lieth, E., Barber, A. J., Xu, B., Dice, C., Ratz, M. J., Tanase, D., Strother, J. M. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes, 1998, 47, 815-20. http://dx. doi. org/10. 2337/diabetes. 47. 5. 815.
5. Barber, A. J., Lieth, E., Khin, S. A., Antonetti, D. A., Buchanan, A. G., Gardner, T. W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest., 1998, 102, 783-91. http://dx. doi. org/10. 1172/ jci2425.
6. Mohr, S., Xi, X., Tang, J., Kern, T. S. Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes, 2002, 51, 1172-9. http://dx. doi. org/10. 2337/diabetes. 51. 4. 1172.
7. Ola, M. S., Nawaz, M. I., Siddiquei, M. M., Al-Amro, S., Abu, El-Asrar, A. M. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. J. Diabetes Compl., 2012, 26(1), 56-64. http://dx. doi. org/10. 1016/jjdiacomp. 2011. 11. 004.
8. Tarr, J. M., Kaul, K., Chopra, M., Kohner, E. M., Chibber, R. Pathophysiology of Diabetic Retinopathy. ISRN Ophthalmol., 2013, 343560.
9. Zhong, Y., Li, J., Chen, Y., Wang, J. J., Ratan, R., Zhang, S. X. Activation of endoplasmic reticulum stress by hyperglycemia is essential for Müller cell-derived inflammatory cytokine production in diabetes. Diabetes, 2012, 61, 492-504. http://dx. doi. org/10. 1007/ s00125-010-1900-z.
10. Zong, H., Ward, M., Madden, A., Yong, P. H., Limb, G. A., Curtis, T. M., Stitt, A. W. Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). Diabetologia, 2010, 53, 2656-66.
11. Diederen, R. M., La Heij, E. C., Deutz, N. E., Kijlstra, A., Kessels, A. G., van Eijk, H. M., Liem, A. T., Dieudonné, S., Hendrikse, F. Increased glutamate levels in the vitreous of patients with retinal detachment. Exp. Eye Res., 2006, 83, 45-50. http://dx. doi. org/ 10. 1016/j. exer. 2005. 10. 031.
12. Yu, X. H., Zhang, H., Wang, Y. H., Liu, L. J., Teng, Y., Liu, P. Time-dependent reduction of glutamine synthetase in retina of diabetic rats. Exp. Eye Res., 2009, 89, 967-71. http://dx. doi. org/10. 1016/ j. exer. 2009. 08. 006.
13. Ola, M. S., Hosoya, K., LaNoue, K. F. Regulation of glutamate metabolism by hydrocortisone and branched chain keto acids in cultured rat retinal Müller cells (TR-MUL). Neurochem. Int., 2011, 59, 656-63. http://dx. doi. org/10. 1016/j. neuint. 2011. 06. 010.
14. Zhang, Y., Bhavnani, B. R. Glutamate-induced apoptosis in neuronal cells is mediated via caspase-dependent and independent mechanisms involving calpain and caspase-3 proteases as well as apoptosis inducing factor (AIF) and this process is inhibited by equine estrogens. BMC Neurosci., 2006, 15, 749. DOI: 10. 1186/1471-2202-7-49.
15. Gowda, K., Zinnanti, W. J., LaNoue, K. F. The influence of diabetes on glutamate metabolism in retinas. J. Neurochem., 2011, 117, 309-20. http://dx. doi. org/10. 1111/j. 1471-4159. 2011. 07206. x.
16. Jiang, H., Du, J., He, T., Qu, J., Song, Z., Wu, S. Increased D-serine in the aqueous and vitreous humour in patients with proliferative diabetic retinopathy. Clin. Exper. Ophthalmol., 2014. doi: 10. 1111/ceo. 12329.
17. Jiang, H., Fang, J., Wu, B., Yin, G., Sun, L., Qu, J., Barger, S. W., Wu, S. Overexpression of serine racemase in retina and overproduction of D-serine in eyes of streptozotocin-induced diabetic retinopathy. J. Neuroinflamm., 2011, 8, 119. doi: 10. 1186/1742-2094-8-119.
18. Stevens, E. R., Esguerra, M., Kim, P. M., Newman, E. A., Snyder, SH, Zahs, K. R., Miller, R. F. D-serine and serine racemase are present in the vertebrate retina and contribute to the physiological activation of NMDA receptors. Proc. Natl. Acad. Sci., 2003, 100(11), 6789-94. http://dx. doi. org/10. 1073/pnas. 1237052100.
19. Hama, Y., Katsuki, H., Tochikawa, Y., Suminaka, C., Kume, T., Akaike, A. Contribution of endogenous glycine site NMDA agonists to excitotoxic retinal damage in vivo. Neurosci. Res., 2006, 56(3), 279-85.
20. Brazionis, L., Rowley, K. Sr., Itsiopoulos, C., Harper, C. A., O'Dea, K. Homocysteine and diabetic retinopathy. Diabetes Care, 2008, 31, 50-6. DOI: 10. 2337/dc07-0632.
21. Lim, C. P., Loo, A. V., Khaw, K. W., Sthaneshwar, P., Khang, T. F., Hassan, M., Subrayan, V. Plasma aqueous and vitreous homocysteine levels in proliferative diabetic retinopathy. Br. J. Ophthalmol., 2012, 96, 704-7. http://dx. doi. org/10. 1136/bjophthalmol-2011-301044.
22. Wijekoon, E. P., Brosnan, M. E., Brosnan, J. T. Homocysteine metabolism in diabetes. Biochem. Soc. Trans, 2007, 35, 1175-9. DOI: 10. 1042/BST0351175.
23. Wright, A. D., Martin, N., Dodson, P. M. Homocysteine, folates, and the eye. Eye (Lond), 2008, 22, 989-93. DOI: 10. 1038/sj. eye. 6703061.
24. Naggar, H., Ola, M. S., Moore, P., Huang, W., Bridges, C. C., Ganapathy, V., Smith, S. B. Downregulation of reduced-folate transporter by glucose in cultured RPE cells and in RPE of diabetic mice. Invest. Ophthalmol. Vis. Sci., 2002, 43, 556-63. PubMed ID: 11818404.
25. Moore, P., El-sherbeny, A., Roon, P., Schoenlein, P. V., Ganapathy, V., Smith. S. B. Apoptotic cell death in the mouse retinal ganglion cell layer is induced in vivo by the excitatory amino acid homocysteine. Exp. Eye Res., 2001, 73, 45-57. http://dx. doi. org/ 10. 1006/exer. 2001. 1009.
26. Ganapathy, P. S., Perry, R. L., Tawfik, A., Smith, R. M., Perry, E., Roon, P., Bozard, B. R., Ha, Y., Smith, S. B. Homocysteine-mediated modulation of mitochondrial dynamics in retinal ganglion cells. Invest. Ophthalmol. Vis. Sci., 2011, 52, 5551-8. http://dx. doi. org/10. 1167/iovs. 11-7256.
27. Ganapathy, P. S., White, R. E., Ha, Y., Bozard, B. R., McNeil, P. L., Caldwell, R. W., Kumar, S., Black, S. M., Smith, S. B. The role of N-methyl-D-aspartate receptor activation in homocysteine-induced death of retinal ganglion cells. Invest. Ophthalmol. Vis. Sci., 2011, 52, 5515-24. http://dx. doi. org/10. 1167/iovs. 10-6870.
28. Lipton, S. A., Kim, W. K., Choi, Y. B., Kumar, S., D'Emilia, D. M., Rayudu, P. V., Arnelle, D. R., Stamler, J. S. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc. Natl. Acad. Sci. U. S. A, 1997, 94, 5923-8. http://dx. doi. org/10. 1073/pnas. 94. 11. 5923.
29. Chmiel-Perzyńska, I., Perzyński, A., Wielosz, M., Urbańska, E. M. Hyperglycemia enhances the inhibitory effect of mitochondrial toxins and D, L-homocysteine on the brain production of kynurenic acid. Pharmacol. Rep., 2007, 59, 268-73. PubMed ID: 17652826.
30. Zwilling, D., Huang, S. Y., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H. Q., Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E. W., Louie, J. Y., Wu, T., Scearce-Levie, K., Patrick, C., Adame, A., Giorgini, F., Moussaoui, S., Laue, G., Rassoulpour, A., Flik, G., Huang, Y., Muchowski, J. M., Masliah, E., Schwarcz, R., Muchowski, P. J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell, 2011, 145, 863-74. http://dx. doi. org/10. 1016/j. cell. 2011. 05. 020.
31. Silva, K. C., Rosales, M. A., Biswas, S. K., Lopes de Faria, J. B., Lopes de Faria, J. M. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes, 2009, 58, 1382-90. http://dx. doi. org/10. 2337/ db09-0166.
32. Kurihara, T., Ozawa, Y., Nagai, N., Shinoda, K., Noda, K., Imamura, Y., Tsubota, K., Okano, H., Oike, Y., Ishida, S. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes, 2008, 57, 2191-8. http://dx. doi. org/10. 2337/db07-1281.
33. Wilkinson-Berka, J. L. Angiotensin and diabetic retinopathy. Int. J. Biochem. Cell Biol., 2006, 38, 752-65. http://dx. doi. org/10. 1016/ j. biocel. 2005. 08. 002.
34. Ola MS, Ahmed MM, Abuohashish HM, Al-Rejaie SS, Alhomida AS. Telmisartan ameliorates neurotrophic support and oxidative stress in the retina of streptozotocin-induced diabetic rats. Neurochem. Res., 2013, 38(8), 1572-9. http://dx. doi. org/10. 1007/s11064-013-1058-4.
35. Kowluru, R. A., Chan, P. S. Oxidative stress and diabetic retinopathy. Exp. Diabetes Res., 2007, 2007, 43603. http://dx. doi. org/ 10. 1155/2007/43603.
36. Kaneto, H., Katakami, N., Matsuhisa, M., Matsuoka, T. A. Role of reactive oxygen species: In the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm., 2010, 2010, 453892. http://dx. doi. org/10. 1155/2010/453892.
37. Zheng, L., Kern, T. S. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front. Biosci., 2009, 14, 3974-87. DOI: 10. 2735/3505.
38. Lam, C. S., Benzie, I. F., Choi, S. W. Relationships among diabetic retinopathy, antioxidants, and glycemic control. Optom. Vis. Sci., 2011, 88, 251-56. http://dx. doi. org/10. 1097/opx. 0b013e318208494a.
39. Park, K. S., Kim, S. S., Kim, J. C., Kim, H. C., Im, Y. S., Ahn, C. W., Lee, H. K. Serum and tear levels of nerve growth factor in diabetic retinopathy patients. Am. J. Ophthalmol., 2008, 145, 432-7. http://dx. doi. org/10. 1016/j. ajo. 2007. 11. 011.
40. Mattson, M. P., Maudsley, S., Martin, B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci., 2004, 27, 589-94. http://dx. doi. org/ 10. 1016/j. tins. 2004. 08. 001.
41. Nagahara, A. H., Tuszynski, M. H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov., 2011, 10, 209-19. http://dx. doi. org/10. 1038/nrd3366.
42. Carmeliet, P., Tessier-Lavigne, M. Common mechanisms of nerve and blood vessel wiring. Nature, 2005, 436, 193-200. http://dx. doi. org/10. 1038/nature03875.
43. Eichmann, A., Makinen, T., Alitalo, K. Neural guidance molecules regulate vascular remodeling and vessel navigation. Genes Dev., 2005, 19, 1013-21. http://dx. doi. org/10. 1101/gad. 1305405.
44. Suchting, S., Bicknell, R., Eichmann, A. Neuronal clues to vascular guidance. Exp. Cell Res., 2006, 312, 668-75. http://dx. doi. org/10. 1016/j. yexcr. 2005. 11. 009.
45. Nagahara, A. H., Tuszynski, M. H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov., 2011, 10, 209-19. http://dx. doi. org/10. 1038/nrd3366.
46. Yoshii, A., Constantine-Paton, M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev. Neurobiol., 2010, 70, 304-22. DOI: 10. 1002/dneu. 20765.
47. Cohen-Cory, S., Kidane, A. H., Shirkey, N. J., Marshak, S. Brain-derived neurotrophic factor and the development of structural neuronal connectivity. Dev. Neurobiol., 2010, 70, 271-88. DOI: 10. 1002/dneu. 20774.
48. Ola, M. S., Nawaz, M. I., El-Asrar, A. Reduced levels of brain derived neurotrophic factor (BDNF) in the serum of diabetic retinopathy patients and in the retina of diabetic rats. Cell Mol. Neurobiol., 2013, 33, 359-67. http://dx. doi. org/10. 1007/s10571- 012-9901-8.
49. Barhwal, K., Hota, S. K., Prasad, D., Singh, S. B., Ilavazhagan, G. Hypoxia-induced deactivation of NGF-mediated ERK1/2 signaling in hippocampal cells: Neuroprotection by acetyl-L-carnitine. J. Neurosci. Res., 2008, 86, 2705-2721. http://dx. doi. org/10. 1002/ jnr. 21722.
50. Barnstable, C. J., Tombran-Tink, J. Neuroprotective and antiangiogenic actions of PEDF in the eye: Molecular targets and therapeutic potential. Prog. Retin. Eye Res., 2004, 23, 561-577. http://dx. doi. org/10. 1016/j. preteyeres. 2004. 05. 002.
51. Shen, X., Xie, B., Cheng, Y., Jiao, Q., Zhong, Y. Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy. Ocul. Immunol. Inflamm, 2011, 19, 246-54. http://dx. doi. org/10. 3109/09273948. 2011. 580073.
52. Barber, A. J., Lieth, E., Khin, S. A., Antonetti, D. A., Buchanan, A. G., Gardner, T. W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest., 1998, 102, 783-791. http://dx. doi. org/10. 1172/jci2425.
53. Barber, A. J., Antonetti, D. A., Kern, T. S., Reiter, C. E., Soans, R. S., Krady, J. K., Levison, S. W., Gardner, T. W., Bronson, S. K. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest. Ophthalmol. Vis. Sci., 2005, 46, 2210-2218. http://dx. doi. org/10. 1167/iovs. 04-1340.
54. Barber, A. J., Nakamura, M., Wolpert, E. B., Reiter, C. E., Seigel, G. M., Antonetti, D. A., Gardner, T. W. Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. J. Biol. Chem., 2001, 276, 32814-32821. http://dx. doi. org/10. 1074/ jbc. m104738200.
55. Reiter, C. E., Wu, X., Sandirasegarane, L., Nakamura, M., Gilbert, K. A., Singh, R. S., Fort, P. E., Antonetti, D. A., Gardner, T. W. Diabetes reduces basal retinal insulin receptor signaling: Reversal with systemic and local insulin. Diabetes, 2006, 55, 1148-1156. http://dx. doi. org/10. 2337/diabetes. 55. 04. 06. db05-0744.
56. Kondo, T., Kahn, C. R. Altered insulin signaling in retinal tissue in diabetic states. J. Biol. Chem., 2004, 279, 37997-38006. http://dx. doi. org/10. 1074/jbc. m401339200.
57. Becerra, S. P., Amaral, J. Erythropoietin--an endogenous retinal survival factor. N. Engl. J. Med., 2002, 347, 1968-70. http://dx. doi. org/10. 1056/nejmcibr022629.
58. Shen, J., Wu, Y., Xu, J. Y., Zhang, J., Sinclair, S. H., Yanoff, M., Xu, G., Li, W., Xu, G. T. ERK-and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest. Ophthalmol. Vis. Sci., 2010, 51, 35-46. http://dx. doi. org/10. 1167/iovs. 09-3544.
59. Chen, J., Connor, K. M., Aderman, C. M., Smith, L. E. Erythropoietin deficiency decreases vascular stability in mice. J. Clin. Invest., 2008, 118, 526-33. http://dx. doi. org/10. 1172/jci33813.
60. Grant, M. B., Boulton, M. E., Ljubimov, A. V. Erythropoietin: when liability becomes asset in neurovascular repair. J. Clin. Invest., 2008, 118, 467-70. http://dx. doi. org/10. 1172/jci34643.
61. Weber, M., Bonaventure, N., Sahel, J. A. Protective role of excitatory amino acid antagonists in experimental retinal ischemia. Graefes. Arch. Clin. Exp. Ophthalmol., 1995, 233, 360-5. http://dx. doi. org/10. 1007/bf00200485.
62. Kusari, J., Zhou, S., Padillo, E., Clarke, K. G., Gil, D. W. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest. Ophthalmol. Vis. Sci., 2007, 48, 5152-5159. http://dx. doi. org/10. 1167/iovs. 07-0427.
63. Martin, P. M., Roon, P., van Ells, T. K., Ganapathy, V., Smith, S. B. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest. Ophthalmol. Vis. Sci., 2004, 45, 3330-3336. http://dx. doi. org/10. 1167/iovs. 04-0247.
64. Ola, M. S., Xu, Y., Barber, A. J., Lanove, K. F. Gabapentin ameliorates apoptosis of the diabetic retina. ARVO meeting abstract, 2007, 48, 632.
65. Chen, H., Weber, A. J. BDNF enhances retinal ganglion cell survival in cats with optic nerve damage. Invest. Ophthalmol. Vis. Sci., 2001, 42, 966-74. PubMed ID: 11274073.
66. Lom, B., Cogen, J., Sanchez, A. L., Vu, T., Cohen-Cory, S. Local and target-derived brain-derived neurotrophic factor exert opposing effects on the dendritic arborization of retinal ganglion cells in vivo. J. Neurosci., 2002, 22, 7639-49. PubMed ID: 12196587.
67. Pinzón-Duarte, G., Arango-González, B., Guenther, E., Kohler, K. Effects of brain-derived neurotrophic factor on cell survival, differentiation and patterning of neuronal connections and Müller glia cells in the developing retina. Eur. J. Neurosci., 2004, 19, 1475-1484. http://dx. doi. org/10. 1111/j. 1460-9568. 2004. 03252. x.
68. Hu, Y., Cho, S., Goldberg, J. L. Neurotrophic effect of a novel TrkB agonist on retinal ganglion cells. Invest. Ophthalmol. Vis. Sci, 2010, 51, 1747-1754. DOI: 10. 1167/iovs. 09-4450.
69. Sánchez-Migallón, M. C., Nadal-Nicolás, F. M., Jiménez-López, M., Sobrado-Calvo, P., Vidal-Sanz, M., Agudo-Barriuso, M. Brain derived neurotrophic factor maintains Brn3a expression in axotomized rat retinal ganglion cells. Exp. Eye Res., 2011, 92, 260-267. http://dx. doi. org/10. 1016/j. exer. 2011. 02. 001.
70. Min, D., Xiao-Bo, X., Si-Qi, X. BDNF regulates GLAST and glutamine synthetase in mouse retinal Müller cells. J. Cell Physiol., 2011. http://dx. doi. org/10. 1002/jcp. 22762.
71. Azadi, S., Johnson, L. E., Paquet-Durand, F., Perez, M. T., Zhang, Y., Ekström, P. A., van Veen, T. CNTF + BDNF treatment and neuroprotective pathways in the rd1 mouse retina. Brain Res., 2007, 1129, 116-129. http://dx. doi. org/10. 1002/jcp. 22762.
72. Takita, H., Yoneya, S., Gehlbach, P. L., Duh, E. J., Wei, L. L., Mori, K. Retinal neuroprotection against ischemic injury mediated by intraocular gene transfer of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci., 2003, 44, 4497-504. http://dx. doi. org/ 10. 1167/iovs. 03-0052.
73. Yoshida, Y., Yamagishi, S., Matsui, T., Jinnouchi, Y., Fukami, K., Imaizumi, T., Yamakawa, R. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab. Res. Rev., 2009, 25, 678-86. http://dx. doi. org/10. 1002/dmrr. 1007.
74. Nishijima, K., Ng, Y., Zhong, L., Bradley, J., Schubert, W., Jo, N., Akita, J., Samuelsson, S. J., Robinson, G. S., Adamis, A. P. Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury. Am. J. Pathol., 2007, 171, 53-67. http://dx. doi. org/10. 2353/ajpath. 2007. 061237.
75. Li, Y., Zhang, F., Nagai, N., Tang, Z., Zhang, S., Scotney, P., Lennartsson, J., Zhu, C., Qu, Y., Fang, C. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J. Clin. Invest., 2008, 118, 913-923. http://dx. doi. org/10. 1210/edrv. 18. 1. 0292.
76. Bikfalvi, A., Klein, S., Pintucci, G., Rifkin, D. B. Biological roles of fibroblast growth factor-2. Endocr. Rev., 1997, 18, 26-45.
77. Molteni, R., Lipska, B. K., Weinberger, D. R., Racagni, G., Riva, M. A. Developmental and stress-related changes of neurotrophic factor gene expression in an animal model of schizophrenia. Mol. Psychiatry, 2001, 6, 285-92. http://dx. doi. org/10. 1038/sj. mp. 4000865.
78. Reiter, C. E., Sandirasegarane, L., Wolpert, E. B., Klinger, M., Simpson, I. A., Barber, A. J., Antonetti, D. A., Kester, M., Gardner, T. W. Characterization of insulin signaling in rat retina in vivo and ex vivo. Am. J. Physiol. Endocrinol. Metab., 2003, 285, E763-74. PubMed ID: 12799319.
79. Zhang, J., Wu, Y., Jin, Y., Ji, F., Sinclair, S. H., Luo, Y., Xu, G., Lu, L., Dai, W., Yanoff, M., Li, W., Xu, G. T. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol. Vis. Sci., 2008 49(2), 732-42. http://dx. doi. org/10. 1167/iovs. 07-0721.
80. Wang, Q., Gorbey, S., Pfister, F., Höger, S., Dorn-Beineke, A., Krügel, K., Berrone, E., Wu, L., Korff, T., Lin, J., Busch, S., Reichenbach, A., Feng, Y., Hammes, H. P. Long-term treatment with suberythropoietic Epo is vaso-and neuroprotective in experimental diabetic retinopathy. Cell Physiol. Biochem., 2011, 27, 769-82. http://dx. doi. org/10. 1159/000330085.
81. McVicar, C. M., Hamilton, R., Colhoun, L. M., Gardiner, T. A., Brines, M., Cerami, A., Stitt, A. W. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes, 2011, 60, 2995-3005. http://dx. doi. org/10. 2337/db11-0026.
82. Sasaki, M., Ozawa, Y., Kurihara, T., Kubota, S., Yuki, K., Noda, K., Kobayashi, S., Ishida, S., Tsubota, K. Neurodegenerative influence of oxidative stress in the retina of a murine model of diabetes. Diabetologia, 2010, 53, 971-979. http://dx. doi. org/10. 1007/s00125-009-1655-6.
83. Silva, K. C., Rosales, M. A., Hamassaki, D. E., Saito, K. C., Faria, A. M., Ribeiro, P. A., Faria, J. B., Faria, J. M. Green tea is neuro-protective in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci., 2013, 54, 1325-36. http://dx. doi. org/10. 1167/iovs. 12-10647.
84. Balakumar, P., Rohilla, A., Krishan, P. The multifaceted therapeutic potential of benfotiamine. Pharmacol. Res., 2010, 61, 482-88 http://dx. doi. org/10. 1016/j. phrs. 2010. 02. 008.
85. Du, X., Edelstein, D., Brownlee, M. Oral benfotiamine plus alpha-lipoic acid nor malises complication-causing pathways in type 1 diabetes. Diabetologia, 2008, 51, 1930-32. http://dx. doi. org/10. 1007/ s00125-008-1100-2.
86. Garcia-Medina, J. J., Pinazo-Duran, M. D., Garcia-Medina, M. A 5-year follow-up of antioxidant supplementation in type 2 diabetic retinopathy. Eur. J. Ophthalmol., 2011, 21, 637-43. http://dx. doi. org/10. 5301/ejo. 2010. 6212.
87. Yamagishi, S., Matsui, T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr. Pharm. Biotechnol., 2011, 12, 36228. DOI: 10. 2174/138920111794480534.
88. Muriach, M., Bosch-Morell, F., Alexander, G., Blomhoff, R., Barcia, J., Arnal, E., Almansa, I., Romero, F. J., Miranda, M. Lutein effect on retina and hippocampus of diabetic mice. Free Radic. Biol. Med., 2006, 41, 979-84. http://dx. doi. org/10. 1016/. freeradbiomed. 2006. 06. 023.
89. Kowluru, R. A., Kanwar, M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr. Metab (Lond). 2007, 16, 4, 8. http://dx. doi. org/10. 1186/1743-7075-4-8.
90. Gupta, S. K., Kumar, B., Nag, T. C., Agrawal, S. S., Agrawal, R., Agrawal, P., Saxena, R., Srivastava, S. Curcumin prevents experimental diabetic retinopathy in rats through its hypoglycemic, antioxidant, and anti-inflammatory mechanisms. J. Ocul. Pharmacol. Ther., 2011, 27, 123-30. http://dx. doi. org/10. 1089/jop. 2010. 0123.
91. Mancino, R., Di Pierro, D., Varesi, C., Cerulli, A., Feraco, A., Cedrone, C., Pinazo-Duran, M. D., Coletta, M., Nucci, C. Lipid peroxidation and total antioxidant capacity in vitreous, aqueous humor, and blood samples from patients with diabetic retinopathy. Mol Vis. 2011, 17, 1298-1304. PubMed ID: 21633716.
92. Wong, T. Y., Simó, R., Mitchell, P. Fenofibrate-a potential systemic treatment for diabetic retinopathy? Am. J. Ophthalmol., 2012, 154, 6-12. http://dx. doi. org/10. 1016Zj. ajo. 2012. 03. 013.